Loading…

Medical Research Finder

meRfi® Microbiome - The Digital Gut Microbiome Reference (incl. AI Chat)
Prebiotics, Probiotics, FMT / Manipulators of the Intestinal Microbiota

AuthorsReferences (Sources)

Paclitaxel + Trastuzumab & Breast Cancer / Mammacarcinoma (HER2+)

Welcome to meRfi Microbiome!

Please register to continue your trial period!

meRfi Microbiome provides you with up-to-date, evidence-based insights on the gut microbiota and related health topics.

Access our ever-expanding digital library and get personalized answers through our interactive AI chat platform.

Start your free trial and transform your understanding of the gut microbiota today!

The authors found in NCT00542451 - Paclitaxel + Trastuzumab & Breast Cancer / Mammacarcinoma (HER2 m) that adjuvant paclitaxel and trastuzumab lead to great long-term results. Longer follow-ups confirm this. Small HER2-positive tumors have similar PAM50 subtypes as larger ones.
Tolaney et al. 2019
…

Adjuvant Trastuzumab Emtansine Versus Paclitaxel in Combination With Trastuzumab for Stage I HER2Positive Breast Cancer (ATEMPT): A Randomized Clinical Trial
Tolaney et al. 2021 JCO 39: 2375–2385
Adjuvant treatment with paclitaxel plus trastuzumab for node-negative breast cancer: real-life experience
Diker et al. 2022 Future Oncology 18: 323-331
Seven-Year Follow-Up Analysis of Adjuvant Paclitaxel and Trastuzumab Trial for Node-Negative, Human Epidermal Growth Factor Receptor 2-Positive Breast Cancer
Tolaney et al. 2019
Survival, Pathologic Response, and Genomics in CALGB 40601 (Alliance), a Neoadjuvant Phase III Trial of Paclitaxel-Trastuzumab With or Without Lapatinib in HER2-Positive Breast Cancer
Fernandez-Martinez et al. 2020 JCO 38: 4184–4193

7/1/2026